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Abstract
Background: The purpose of the present study was to examine the efficacy of targeting inflammation as a means
of improving mood following spinal cord injury (SCI) and explore the potential mechanisms of action.
Methods: The study was a randomized, parallel-group, controlled, clinical trial (NCT02099890) whereby 20
participants with varying levels and severities of SCI were randomized (3:2) to either the treatment group, consisting
of a 12-week anti-inflammatory diet, or control group. Outcome measures were assessed at baseline, 1 and
3 months, and consisted of CES-D scores of depression, markers of inflammation as assessed by various pro- and
anti-inflammatory cytokines and several amino acids related to depression.
Results: A significant group × time interaction was found for CES-D (Center for Epidemiologic studies Depression
Scale) score (p = 0.01), the TRP/LNAA (tryptophan/large neutral amino acid) ratio (p = 0.04), the composite score of
pro-inflammatory cytokines (p = 0.04), IL-1β (interleukin-1 beta) (p = 0.04), and IFN-γ (interferon gamma) (p = 0.03).
Pearson’s r correlation showed significance between the ΔIL-1β and both the ΔCES-D score (r = 0.740, p < 0.01) and
the ΔKYN/TRP (kynurenine/tryptophan) ratio (r = 0.536, p = 0.02). The ΔKYN/TRP ratio was also significantly correlated
with the ΔCES-D score (r = 0.586, p = 0.01). Mediation analysis showed that the relationship between the ΔKYN/TRP
ratio and the ΔCES-D score was mediated by the ΔIL-1β. Subgroup analysis showed that participants with high
CES-D scores had significantly higher concentrations of IL-1β, and all correlations were maintained or strengthened
within this subgroup.
Conclusions: Overall, the results demonstrated the effectiveness of targeting inflammation as a means of
improving mood in SCI, with potential mechanisms relating to the reduction in IL-1β and improvements in levels of
neuroactive compounds related to the kynurenine pathway. Due to the limited sample size, results should be
interpreted with caution; however, they are worthy of further examination due to the potential impact of
inflammation on depression.
Trial registration: ClinicalTrials.gov ID: NCT02099890.
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Background
Individuals with major depressive disorder (MDD) are
commonly reported to demonstrate immune dysfunction
in the form of chronic inflammation, and likewise, indi-
viduals with chronic inflammatory disorders are more
prone to MDD [1–3]. Such a state has been proposed to
be a contributing factor to symptoms of depression due
to the complex bidirectional communicatory pathways
between various systems of the body. In this respect,
chronic inflammation may impact the endocrine and
nervous systems causing respective imbalances in critical
hormones and neuroactive compounds which may ul-
timately influence behavior and contribute to depressive
symptoms [4].
Various pro-inflammatory mediators possess the ability
to influence the function of transporters, enzymes, and
receptors both in the periphery and within the brain.
Certain pro-inflammatory cytokines are able to travel
from the periphery to the brain via both active and passive
mechanisms [5, 6]. Once in the brain, pro-inflammatory
cytokines such as IL-1β (interleukin-1 beta) and TNF-α
(tumor necrosis factor alpha) can alter extra-cellular con-
centrations of serotonin (5-HT) by upregulating corre-
sponding transporters (SERT) [7–9]. In this way, such
pro-inflammatory cytokines have the ability to directly re-
duce 5-HT levels within the brain which are associated
with symptoms of depression.
Peripherally, pro-inflammatory cytokines can influence
the regulation of enzymes from critical metabolic path-
ways and induce imbalances in key mood-altering neu-
roactive compounds. The kynurenine pathway is one
such pathway which must be strictly regulated due to its
role as the primary route for tryptophan (TRP) degrad-
ation. Approximately 95 % of this critical 5-HT precur-
sor is metabolized along this pathway, meaning a
cytokine-induced upregulation of TRP degradation may
ultimately result in the reduction in 5-HT levels within
the brain [10, 11]. In the same respect, the increased
degradation of TRP results in elevated levels of TRP me-
tabolites. Certain TRP metabolites such as kynurenine
(KYN) are BBB (blood brain barrier) transportable and
have also been shown to contribute to symptoms of de-
pression when at elevated concentrations within the
brain (see Fig. 1).
A low-grade chronic inflammatory state is very com-
monly reported following spinal cord injury (SCI) as
characterized by elevated levels of circulating pro-
inflammatory mediators [12–16]. This state of immune
dysfunction can be attributed to a variety of factors ran-
ging from the loss of autonomic innervation of lymphoid
organs, endocrine dysfunction, metabolic disorders, and
a heightened risk for secondary health complications
[17]. This population is also far more prone to depres-
sion with rates reaching up to five times (20–40 %) that
of healthy, able-bodied individuals [18, 19]. Suicide rates
are also far more prevalent among this population with
rates ranging from three to five times greater than
healthy able-bodied individuals [20, 21]. Provided that
traditional pharmaceutical treatments for depression,
such as selective serotonin reuptake inhibitors (SSRIs),
have commonly reported side effects [22], prove ineffect-
ive in approximately 30 % of patients [23], and corres-
pond to high rates of relapse [24], alternative treatments
are needed.
Fig. 1 Tryptophan Metabolism along the kynurenine pathway. a The kynurenine pathway within the periphery and brain under healthy conditions.
Proper enzyme regulation results in a healthy balance of TRP and TRP metabolites. As a result, adequate levels of TRP are available for 5-HT synthesis
and properly regulated SERT proteins ensure that extra-cellular concentrations of 5-HT are not depleted. Healthy levels of TRP metabolites within the
brain (e.g., QUIN) ensure normal activation of NMDA receptors thereby maintaining healthy hippocampal function and proper regulation of the HPA
axis. b The kynurenine pathway within the periphery and brain in a state of chronic inflammation. Elevated levels of pro-inflammatory cytokines cause
upregulation of enzymes such as IDO thereby resulting in an increased breakdown of TRP and production of TRP metabolites. As a result, reduced
levels of TRP are available for the synthesis of 5-HT. Pro-inflammatory cytokines also upregulate SERT proteins causing further depletion of extra-cellular
5-HT. Elevated levels of TRP metabolites within the brain such as QUIN (potent NMDA agonist) result in over-activation of NMDA receptors, neuronal
damage, and potential atrophy. This may also lead to a loss of inhibition of the HPA axis and excessive production of stress hormones
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The link between inflammation and depression may
provide the opportunity to treat the latter by targeting
the immune system via anti-inflammatory strategies. As
there is a need for drastic changes in dietary intake fol-
lowing paralysis, and these changes are typically not
met, the eating habits of individuals with SCI commonly
contribute to a state of chronic inflammation. This pro-
vides the opportunity to reduce inflammation via the im-
plementation of a strict anti-inflammatory diet for the
purposes of assessing the influence of reduced inflam-
matory mediators on mood following SCI. It was hy-
pothesized that reducing inflammation would lead to
corresponding changes in neuroactive compounds and
improvements in mood and depressive symptoms.
Methods
Study design and participants
The study was a randomized, parallel-group clinical trial.
Participant recruitment occurred between September and
November 2014. The study intervention was 12 weeks
and included testing at baseline, 1 and 3 months. Partici-
pants with various levels and severities of SCI were re-
cruited for participation in the study. Additional inclusion
criteria included (1) over the age of 18, (2) SCI of any level
or severity (American Spinal Injury Association A-D), and
(3) at least 2 years post injury. Exclusion criteria included
(1) any contraindications to supplements provided in the
study, (2) unstable dosage of any anti-depressive medica-
tions, (3) an unstable medical condition within 2 weeks
prior to intervention, (4) pregnancy, and (5) breastfeeding.
Participant characteristics are shown in Table 1. Twenty
individuals (10 male, 10 female; age 48.7 ± 13.9 years) with
chronic (4–37 years post injury) SCI (C2-L4; ASIA Im-
pairment Scale [AIS] A-D) were recruited for participation
in the study. Twelve participants were randomly allo-
cated to the treatment group, and were placed on the
12-week anti-inflammatory diet intervention, while eight
were allocated to the control group and received no
intervention. Informed consent was obtained from all
participants. The study was registered as a clinical trial
(clinicaltrials.gov identifier: NCT02099890) and received
ethical approval from the Brock University Research
Ethics Board as well as the Natural Health Products
Directorate of Canada. All data was collected on-site at
Brock University and the Brock-Niagara Center for
Health and Well-being.
Randomization
Randomization was computer-generated by the primary
investigator and stratified by participant gender and age
using permuted blocks of 2 (male/female) and blocks of
3 (<40, 40–60, >60 year). Randomization was 3:2 to ei-
ther the anti-inflammatory diet vs. control.
Anti-inflammatory diet intervention
The anti-inflammatory diet intervention focused on
the elimination of common food intolerances and
inflammation-inducing foods, as well as the introduc-
tion of foods and supplements with established anti-
inflammatory properties. Examples of foods removed
from the diet included those with high glycemic indices
(such as refined wheat products and refined sugars), com-
mon intolerances such as cow’s milk and foods which
negatively influence cardiovascular health such as hy-
drogenated oils. Participants also consumed daily sup-
plements with established anti-inflammatory benefits.
Omega-3 (Now Ultra omega-3) was taken in softgel form,
containing 500 mg EPA and 250 mg DHA, at a dosage of
three per day. Chlorella (Now chlorella) was taken in pill
form, containing 1000 mg, at a dosage of six per day. Anti-
oxidants (CanPrev antioxidant network) were taken in pill
form, containing 100 mg coenzyme Q10, 200 mg n-acetyl-
cysteine, 150 mg mixed tocopherols, 100 mg DL alpha
lipoic acid, 60 mg green tea extract, 5.5 mg zinc, and
100 μg selenium, at a dosage of two per day. Curcumin
(AOR Inflanox) was taken in pill form, containing 400 mg,
at a dosage of three per day. A vegetable-based protein
Table 1 Participant characteristics
Participant Sex Age AIS score Level of
injury
Time since
injury (years)
Treatment
1 F 44 D C5 10
2 M 58 B T10 4
3 F 62 D L3 4
4 F 37 A T3 19
5 M 22 A C7 5
6 M 67 C C2 4
7 M 66 D C5 6
8 F 44 A C7 9
9 F 65 D T6 4
10 F 64 D C3 37
11 M 45 A T6 28
12 M 37 C C4 23
Control
13 F 30 B C5 6
14 F 63 D L4 2
15 M 42 A C5 6
16 F 58 D C5 33
17 M 59 D T4 4
18 F 33 A T1 17
19 M 41 C C4 22
20 M 36 A C5 19
AIS ASIA (American Spinal Injury Association) Impairment Scale
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powder (Progressive Vegessential) containing 27 g of pro-
tein was taken at a dosage of one scoop each morning.
Both the treatment group and control group were
asked to complete a detailed diet record for 7 days at
baseline, as well as 3 days at 1, 2, and 3 months in order
to establish baseline eating habits and assess compliance
throughout the intervention. Food intake was assessed
using The Food Processor (ESHA Inc. 2014, version
10.14.2, Salem, OR). Compliance to the specific anti-
inflammatory diet was also assessed by a detailed ana-
lysis of all diet records. Each food item was categorized
as either “food to consume”, “food to avoid”, or “neutral
food” based on the parameters of the diet participants
were instructed to follow. Food was also categorized into
servings in accordance with Canada’s Food Guide. There-
fore, compliance scores were based on standard servings
of foods subjects were instructed to eat vs. foods they were
instructed to avoid. To account for differences in total en-
ergy intake, compliance scores were expressed as a ratio
of the servings of foods to consume over the total servings
of food (avoid + consume) multiplied by 100. The percent
compliance was then generated.
The treatment group then underwent an information
seminar which explained the diet program followed by a
one-on-one consultation with nutritionists during which
their diet records were reviewed in detail, and necessary
changes were discussed. Participants received information
regarding foods to eat and avoid, a supplement intake
schedule, and a list of approved recipes. Participants in
the treatment group received support via weekly phone
calls from members of our research team as well as a
monitored online support group whereby participants
could share recipes and experiences with one another.
Participants in the control group were asked to maintain
their current diets throughout the duration of the study.
Measurement of serum inflammatory markers and amino
acids
Blood draws (20 ml) were taken from the antecubital
vein of each participant at 1 p.m. at each of the three
testing sessions (baseline, 1 and 3 months). Following
extraction, the whole blood was allowed to clot for
30 min followed by centrifugation at 1000 ×g for 15 min.
Serum was extracted and immediately stored at −80 °C
until later analysis. Inflammatory mediators of interest
included the pro-inflammatory cytokines IL-2, IL-1β, IL-
6, TNF-α, IFN-γ, the acute phase protein CRP, as well as
the anti-inflammatory cytokines IL-4, IL-10, and IL-1RA.
Amino acids of interest included tryptophan, phenylalan-
ine, tyrosine, and branched-chain amino acids (valine, leu-
cine, isoleucine) for the assessment of the TRP/LNAA
ratio. Phenylalanine and tyrosine were also quantified for
the assessment of the PHE/TYR ratio which provides an
indication of phenylalanine (4)-hydroxylase activity. Chronic
inflammation has been shown to impair the activity,
this enzyme thereby causing increases in PHE and an
increase in the PHE/TYR, which provides some indica-
tion of the inflammatory state [25]. Kynurenine levels
were also analyzed for the assessment of the KYN/TRP
ratio. Analysis of pro- and anti-inflammatory cytokines
was performed in triplicate via the Magpix Multiplex
system (EMD Millipore, MA, USA.) and analyzed using
Luminex software. CRP was analyzed in triplicate and
quantified via enzyme-linked immunosorbent assay (R&D
systems, Minneapolis, USA). TRP, Phe, TYR, BCAA, and
KYN were analyzed in triplicate and quantified via
enzyme-linked immunosorbent assay (Immunodiagnos-
tik, Bensheim, Germany; Labor Diagnostika, Nordhorn,
Germany).
Assessment of mood
Participants completed the Center for Epidemiological
Studies Depression Scale (CES-D) at each of the three
testing sessions, as a means of assessing symptoms of
depression. The questionnaire consisted of 20 items re-
lated to depression, and participants were asked to rate
how often they experienced each item over the previous
7-day period. Ratings were based on a 4-point scale in-
cluding “rarely or none of the time” (less than 1 day),
“some or a little of the time” (1–2 days), “occasionally or
a moderate amount of the time” (3–4 days), or “most or
all of the time” (5–7 days). Points for each item ranged
from 0 to 3 depending on frequency, and each item was
summed for a total score ranging from 0 to 60 with
higher scores indicating the presence of more symptom-
atology. A score of 16 points or greater is considered
depressed.
Statistical analysis
Two-way (group × time) repeated measure ANOVA was
performed to investigate possible changes in inflammatory
mediators, amino acids, and CES-D scores across three
testing sessions. Post hoc analyses were used as needed to
compare means when significant group × time interac-
tions were found. These data are expressed as means ±
standard deviations. Correlations between changes in in-
flammatory mediators, amino acids, and CES-D scores
were assessed by means of Pearson’s r correlation. A medi-
ation analysis was performed to assess whether the rela-
tionship between the change in the KYN/TRP ratio and
the change in CES-D score was mediated by the change in
IL-1β. This analysis consisted of four steps of testing: (1)
the association of the independent variable (ΔKYN/TRP
ratio) with the outcome variable (ΔCES-D score), (2) the
association of the independent variable with the mediator
variable (ΔIL-1β), (3) the association of the mediator
variable with the outcome variable after controlling
for independent variable, and (4) whether the effect
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of the independent variable on the dependent variable
was reduced when the mediator was included in the
model. Differences in IL-1β concentrations for sub-
group analysis were assessed using the Student t test.
Statistical significance was set at p ≤ 0.05 for all tests.
Results
All participants from both the treatment and control
group completed the entire 3-month duration of the
study and were included in the analysis. No adverse
events were reported. The participants’ overall compli-
ance to the diet was assessed based on the average of
the three diet records during the study (1, 2, and
3 months). One participant completed all three testing
sessions but failed to produce the 2- and 3-month diet
record. This participant had a dietary compliance over
the first month of 92 %. All other participants completed
each of the required diet records, and overall compliance
ranged from 70 to 100 %, with a mean compliance of
89 %. A detailed analysis regarding specific diet adher-
ence data will be presented elsewhere.
All participants
Change in CES-D scores
Changes in CES-D scores are shown in Table 2. There
was a significant group × time interaction for CES-D
scores (p = 0.01, Cohen’s d = 1.07). Post hoc analysis
showed a significant reduction in CES-D scores in the
treatment group from both baseline to 1 month, as well
as from baseline to 3 months (p = 0.01 and p < 0.01, re-
spectively). Post hoc analysis showed a significant reduc-
tion in CES-D score in the control group from baseline
to 1 month (p = 0.03) but no significant change from
baseline to 3 months (p = 0.74).
Change in serum amino acids
Changes in serum amino acids are shown in Table 2.
There was a significant group × time interaction for the
TRP/LNAA ratio (p = 0.04, Cohen’s d = 0.90). Post hoc
analysis showed a trend toward a reduction in TRP/
LNAA in the treatment group from baseline to 3 months
(p = 0.06). Post hoc analysis showed no change in the
control group at any time point. There was no signifi-
cant group × time interaction for the KYN/TRP ratio
(p = 0.32, Cohen’s d = 0.51) or the PHE/TYR ratio (p =
0.435, Cohen’s d = 0.43). KYN showed a trend toward a
group × time interaction (p = 0.06, Cohen’s d = 0.81).
Change in inflammatory mediators
Changes in serum levels of inflammatory mediators are
shown in Table 3. When considering a composite score
averaging pro-inflammatory cytokines, the two-way
(group × time) ANOVA showed a significant interaction
(p = 0.04, Cohen’s d = 1.02). Post hoc analysis showed
trends toward reductions in the treatment group from
both baseline to 1 month and baseline to 3 months (p =
0.08 and p = 0.10, respectively) and no significant change
in the control group at any time point. When analyzing
each cytokine separately, two-way ANOVA showed sig-
nificant group × time interactions for IFN-γ (p = 0.03,
Cohen’s d = 1.02) and IL-1β (p = 0.04, Cohen’s d = 0.87).
Post hoc analysis showed trends toward reductions in
the treatment group from both baseline to 1 month and
baseline to 3 months for IFN-γ (p = 0.08 and p = 0.09, re-
spectively) and no significant change in the control
group at any time point. Post hoc analysis showed a sig-
nificant reduction in IL-1β in the treatment group from
baseline to 1 month (p = 0.04) and a trend from baseline
to 3 months (p = 0.07) and no significant change in the
Table 2 Change in CES-D score and serum amino acids
Treatment (n = 12) Control (n = 8)
Baseline 1 month 3 months Baseline 1 month 3 months
CES-D score*** 14.5 ± 10.7 6.8 ± 5.6** 6.5 ± 5.0** 13.9 ± 12.0 11.3 ± 10.3* 14.6 ± 13.6
TRP (μmol/L) 89.2 ± 19.4 87.6 ± 28.8 90.7 ± 26.7 107.8 ± 28.1 105.9 ± 20.3 102.6 ± 14.4
Tyrosine (μmol/L) 48.2 ± 17.7 50.5 ± 15.1 41.5 ± 15.2 59.4 ± 17.6 53.7 ± 15.7 62.2 ± 18.3
Phenylalanine (μmol/L) 36.6 ± 13.6 36.8 ± 13.6 33.6 ± 14.8 42.0 ± 16.6 40.8 ± 18.2 46.2 ± 23.4
BCAA (μmol/L) 700.2 ± 462.4 651.3 ± 351.9 467.9 ± 198.5 449.7 ± 105.5 472.2 ± 112.1 534.3 ± 159.2
LNAA (μmol/L) 785.0 ± 468.2 738.6 ± 352.3 543.1 ± 217.3 551.2 ± 108.7 566.8 ± 123.8 642.7 ± 190.3
TRP/LNAA*** 146.9 ± 71.3 133.6 ± 52.3 188.7 ± 90.4 206.3 ± 79.6 194.0 ± 51.2 171.2 ± 49.8
KYN (μmol/L) 2.3 ± 0.7 2.3 ± 0.6 2.1 ± 0.4 1.7 ± 0.4 2.1 ± 0.3 2.1 ± 0.4
PHE/TYR 786.8 ± 232.2 738.1 ± 229.5 809.5 ± 180.4 746.6 ± 247.1 751.08 ± 219.1 732.78 ± 267.2
KYN/TRP 27.0 ± 11.6 28.5 ± 10.9 24.0 ± 6.6 16.8 ± 4.9 20.3 ± 4.7 20.6 ± 6.0
LNAA (large neutral amino acids) is the sum of tyrosine, phenylalanine, and BCAA; TRP/LNAA ratio is calculated as TRP/LNAA × 1000; KYN/TRP ratio is calculated as
KYN/TRP × 1000; and PHE/TYR ratio is calculated as PHE/TYR × 1000
All results are shown as mean ± SD
*Significantly different from baseline with p value ≤0.05
**Significantly different from baseline with p value ≤0.01
***Significant group × time interaction with p value ≤0.05
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control at any time point. Trends toward group × time
interactions were observed for IL-6 (p = 0.10, Cohen’s
d = 0.74), TNF-α (p = 0.10, Cohen’s d = 0.74), and IL-
1RA (p = 0.07, Cohen’s d = 0.79).
Correlational analysis
Pearson’s r correlation coefficients for amino acid, cyto-
kine, and CES-D data are shown in Table 4. The change
in IL-1β was significantly correlated with both the change
in CES-D score (r = 0.740, p < 0.01) and the change in the
KYN/TRP ratio (r = 0.536, p = 0.02). The change in the
KYN/TRP ratio was also significantly correlated with
the change in CES-D score (r = 0.586, p = 0.01). The
relationship between the change in TRP/LNAA ratio
and the change in CES-D score did not reach statistical
significance (r = −0.378, p = 0.10), whereas the relationship
between the change in the TRP metabolite KYN and the
change in CES-D score did reach statistical signifi-
cance (r = 0.705, p < 0.01).
Mediation analysis
A mediation analysis was performed in order to test
whether the change in IL-1β mediated the observed rela-
tionship between the change in KYN/TRP and the
change in CES-D scores. In the first step of the medi-
ation model, the association of the independent variable
with the outcome variable was assessed. This regression
of the change in the KYN/TRP ratio on the change in
CES-D scores (ignoring the change in IL-1β) was signifi-
cant, b = 0.586, t(18) = 3.07, p = 0.01. In step two, the as-
sociation of the independent variable with the mediator
variable was assessed. It was shown that the regression
of the change in the KYN/TRP ratio on the mediator
(change in IL-1 β) was also significant, b = 0.06, t(18) =
2.70, p = 0.02. In step three of the mediation process, the
association of the mediator variable with the outcome
variable after controlling for the independent variable
was assessed. The regression of the change in IL-1β on
the change in CES-D score (controlling for the change
in the KYN/TRP ratio) was significant b = 5.34, t(17) =
3.30, p < 0.01. In the last step, we assessed whether the
effect of the independent variable on the dependent vari-
able was reduced when the mediator was included in the
model. When controlling for the change in IL-1β, the
change in the KYN/TRP ratio was not a significant pre-
dictor of the change in CES-D score, b = 0.25, t(17) =
1.45, p = 0.16. A Sobel test was conducted and found full
mediation in the model (z = 2.04, p = 0.04). Therefore, it
Table 3 Change in inflammatory mediators
Treatment (n = 12) Control (n = 8)
Baseline 1 month 3 months Baseline 1 month 3 months
Pro-inflammatory cytokines
CRP (ng/ml) 4474.7 ± 3578.9 3822.6 ± 3749.4 2865.0 ± 2684.9 2388.1 ± 2928.1 3074.0 ± 3026.4 2458.8 ± 3678.9
IL-2 (pg/ml) 21.3 ± 51.2 15.1 ± 41.7 17.2 ± 42.1 1.7 ± 3.4 2.9 ± 3.6 2.3 ± 3.3
IL-6 (pg/ml) 13.9 ± 28.2 9.2 ± 21.3 9.5 ± 19.3 9.0 ± 10.5 13.8 ± 21.2 13.5 ± 21.9
IL-1β (pg/ml)** 0.9 ± 1.1 0.3 ± 0.3* 0.3 ± 0.2 0.3 ± 0.3 0.4 ± 0.5 0.3 ± 0.2
TNF-α (pg/ml) 12.5 ± 3.6 11.8 ± 5.5 11.2 ± 4.1 9.8 ± 3.9 11.3 ± 6.7 12.9 ± 10.3
IFN-γ (pg/ml)** 52.9 ± 94.0 31.9 ± 57.5 35.0 ± 68.4 28.1 ± 46.8 48.8 ± 84.6 49.6 ± 95.3
Anti-inflammatory cytokines
IL-4 (pg/ml) 7.5 ± 20.8 12.4 ± 23.9 16.2 ± 38.4 19.8 ± 37.2 37.4 ± 83.8 23.8 ± 46.3
IL-10 (pg/ml) 6.5 ± 12.9 11.2 ± 29.7 9.3 ± 22.0 5.9 ± 14.4 5.7 ± 13.7 6.3 ± 14.6
IL-1RA (pg/ml) 33.1 ± 26.2 27.8 ± 18.6 26.3 ± 16.0 60.6 ± 66.6 77.2 ± 77.2 78.8 ± 105.8
Pro-inflammatory cytokines consist of a composite score averaging IL-2, IL-6, IL-1β, TNF-α, and IFN-γ; anti-inflammatory cytokines consist of a composite score
averaging IL-4, IL-10, and IL-1RA
All results are shown as mean ± SD
*Significantly different from baseline with p value ≤0.05
**Significant group × time interaction with p value ≤0.05
Table 4 IL-1β, amino acid, and CES-D correlations
ΔCES-D ΔIL-1β ΔTRP/LNAA ΔKYN/TRP
All participants (n = 20)
ΔCES-D – – – –
ΔIL-1β 0.740** – – –
ΔTRP/LNAA −0.378 0.369 – –
ΔKYN/TRP 0.586** 0.536* 0.345 –
ΔKYN 0.705** 0.657** 0.114 0.730**
Subgroup (CES-D > 16) (n = 8)
ΔCES-D – – – –
ΔIL-1β 0.738* – – –
ΔTRP/LNAA 0.569 0.363 – –
ΔKYN/TRP 0.937** 0.792* 0.436 –
ΔKYN 0.800** 0.825** 0.192 0.823**
*p ≤ 0.05; **p ≤ 0.01
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was found that the change in IL-1β fully mediated the
relationship between the change in the KYN/TRP ratio
and the change in CES-D scores.
Subgroup analysis
A subgroup analysis was performed examining partici-
pants with CES-D scores greater than 16 (indicating de-
pression) from both the treatment group (n = 5) and
control group (n = 3). It was found that participants with
CES-D scores indicating depression had concentrations
of IL-1β which were 73 % higher compared to those with
lower (<16) CES-D scores (p = 0.05). Pearson’s r correl-
ation coefficients for amino acid, cytokine, and CES-D
data are shown in Table 4. The significant relationship
between the change in IL-1β and the change in CES-D
remained in this subgroup (r = 0.738, p = 0.04), and the
relationship between the change in IL-1β and the change
in the KYN/TRP ratio became even stronger (r = 0.792,
p = 0.02). The change in the KYN/TRP ratio and the
change in CES-D was also very strongly correlated in
this subgroup (r = 0.937, p < 0.01). Once again, the
change in the TRP/LNAA and the change in CES-D
were not found to be significantly correlated (r = 0.569,
p = 0.11) while the change in KYN was strongly correlated
with the change in CES-D score (r = 0.800, p = 0.01).
Discussion
The present study successfully obtained reductions in in-
flammatory mediators, modifications in neuroactive com-
pounds, and improvements in mood in individuals with
SCI by means of dietary alterations. As evidence suggests
that inflammation contributes to depression, and SCI is
typically characterized by a state of chronic inflammation
as well as a high prevalence of depression, it was hy-
pothesized that reducing levels of inflammation in this
population would result in both molecular changes and
corresponding improvements in mood.
Mood was significantly improved in the treatment
group as demonstrated by the significant reduction in
CES-D scores. When assessing potential mechanisms for
such changes, a significant group × time interaction for
the TRP/LNAA ratio was found, and post hoc analysis
revealed trends toward an increase in the treatment
group at 1 and 3 months following baseline. TRP is a
critical precursor for 5-HT synthesis in the brain and
competes for transportation across the BBB against
other LNAA via common transport mechanisms. As
such, an increase in the TRP/LNAA ratio signifies
heightened TRP availability and would be expected to
relate to improvements in mood. However, the relation-
ship between the change in the TRP/LNAA ratio and
the change in CES-D scores did not reach statistical sig-
nificance (p = 0.10).
A significant group × time interaction was found for
both IFN-γ and IL-1β, and post hoc analysis showed
trends toward reduction for IFN-γ at 1 and 3 months
and a significant reduction for IL-1β at 1 month and
trend toward reduction at 3 months. Trends toward
group × time interactions were also found for IL-6,
TNF-α, and IL-1RA. Of these changes, only the reduc-
tion in IL-1β was shown to significantly correlate with
the reduction in CES-D score. As IL-1β is capable of
gaining access to the brain via leaky sites at the circum-
ventricular organs or by crossing the BBB or via special-
ized active transporters, it may be possible for it to
impose a direct influence [5, 6]. Once in the brain, IL-1β
has been shown to activate 5-HT transporters (SERT),
thereby stimulating the reuptake of 5-HT from the syn-
aptic cleft, leading to its functional depletion [7–9].
Although it was not possible to directly assess SERT or
5-HT levels within the brain, it is possible for IL-1β to
have contributed to changes in mood by means of such
direct mechanisms.
The change in IL-1β was also significantly correlated
with the change in the KYN/TRP ratio. The KYN/TRP
ratio can represent the activity of either indoleamine
2,3-dioxygenase (IDO) or tryptophan 2,3 dioxygenase
(TDO). Both are critical enzymes of the kynurenine
pathway responsible for the degradation of TRP into
KYN. TDO is, however, mainly expressed in the liver
and not regulated by the immune system [26]. IDO is an
immunoregulated enzyme, and elevations in the KYN/
TRP ratio have been previously shown to be significantly
correlated with increases in IFN-γ activity [27] as well as
elevations in neopterin; a molecule synthesized by mac-
rophages upon stimulation by IFN-γ, an indicator of a
pro-inflammatory status [28]. This strongly suggests that
IDO is the main enzymatic contributor to changes in the
KYN/TRP ratio in response to changes in inflammation.
Additional pro-inflammatory cytokines, including IL-1β,
have been shown to upregulate IDO activity, thereby in-
creasing the rate of TRP metabolism and production of
TRP metabolites [29]. This selective TRP metabolism
can lead to reductions in the TRP/LNAA ratio thereby
limiting TRP availability for the synthesis of 5-HT. Add-
itionally, the excessive breakdown of TRP results in the
increased production of TRP metabolites which has also
been shown to play an important role in factors related
to depression. As the change in the KYN/TRP ratio was
also significantly correlated with the change in CES-D
scores, it may be possible that IL-1β influenced depres-
sion via such IDO-related mechanisms. Based on these
findings, a mediation analysis was performed to further
address the extent to which the link between change in
the KYN/TRP ratio and change in the CES-D scores
were mediated by change in the IL-1β. The analysis sug-
gested that the relationship between change in the KYN/
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TRP and change in the CES-D was fully mediated by
change in the IL-1β.
In addition to the potential reduction in TRP availability
as shown by the TRP/LNAA ratio, a cytokine-induced up-
regulation of IDO activity may result in elevations in TRP
metabolites. Several TRP metabolites, including KYN, are
BBB transportable and can be neurotoxic when at elevated
concentrations within the brain. As in the periphery, once
in the brain, KYN can be further metabolized along the
kynurenine pathway into other metabolites which have
been shown to influence depression. One such metabolite,
quinolinic acid (QUIN), acts as a potent agonist of
the N-methyl-D-aspartate (NMDA) receptor which is
densely populated on the hippocampus and plays a critical
role in synaptic plasticity. Elevated concentrations of
QUIN may result in NMDA over-activity resulting in an
increased calcium influx leading to corresponding neur-
onal damage and potential atrophy [30]. Smaller hippo-
campal volumes in individuals with MDD have been
commonly reported [31–34]. As the hippocampus plays
an important role concerning the inhibition of HPA axis,
hippocampal atrophy may result in an upregulated HPA
axis and excessive glucocorticoid production from the ad-
renal gland. Hyperactivity of the HPA axis and elevated
levels of stress hormones have also been commonly re-
ported in individuals with MDD (see Fig. 1) [35, 36].
Both the reduction in the TRP/LNAA ratio and in-
crease in TRP metabolites have the potential to influence
depression via the aforementioned mechanisms. How-
ever, the fact that the change in KYN was related to the
change in CES-D scores (while the change in TRP/
LNAA was not) may suggest that the production of TRP
metabolites had a larger impact on such mood changes.
Similar findings have been demonstrated by Sublette et
al. 2011, whereby levels of KYN have been shown to be
elevated in suicide attempters with MDD and correlated
with attempt status, while TRP was not related. Further,
Sublette et al. found a correlation between the cytokine
activation marker neopterin and the KYN/TRP ratio
suggesting that KYN production may have been influ-
enced by inflammation [37].
Additional subgroup analysis on those with baseline
CES-D scores greater than 16 (suggesting depression) fur-
ther implicated a role for IL-1β in depression as levels
were shown to be 73 % higher than in those with CES-D
scores indicating a lack of depression. Further, all relation-
ships between IL-1β, the KYN/TRP ratio and CES-D
scores, were maintained or strengthened in this subgroup
including a very strong relationship between the change in
the KYN/TRP ratio and the change in CES-D scores. Des-
pite the small sample size, it also worth noting that for the
five participants in the treatment group who began with
scores indicating depression, all five reached scores below
16 within the first month of the intervention.
The above mechanisms may explain the link between
the dietary-induced reductions in inflammation and the
improvements in mood as assessed by CES-D scores.
SCI is associated with substantial alterations in nutrient
requirements and energy demands as well as an in-
creased risk for numerous metabolic disorders and acute
infections. Appropriate dietary alterations are therefore a
suitable method of reducing inflammation and have a
number of established mechanisms of action ranging
from altered gene transcription, changes in cell mem-
brane composition, improved enzyme regulation, as
well as improvements in metabolic health and body
composition [38].
Common pharmaceutical treatment modalities for de-
pression, such as selective serotonin reuptake inhibitors
(SSRIs), are popular due to their ability to relieve symp-
toms in a relatively short period of time by acting on
SERT proteins to help increase extra-cellular 5-HT
levels. SSRI-use is, however, associated with a number of
side effects [22] and only provides transient relief of
symptoms as it does not target the etiological basis of
the disorder. SSRIs have also been shown to be ineffect-
ive in approximately 30 % of patients [23] of whom a
particularly elevated inflammatory state is typically re-
ported [39, 40]. Additionally, of those who do respond
to treatment, an estimated 20–80 % will relapse within
the first 1–5 years following initial treatment [24]. As
such, there is a clear need for a more sustainable, long-
term treatment, free from the many side effects that co-
incide with prolonged use of traditional pharmaceutical
treatments.
Whether anti-inflammatory strategies could be used as
a stand-alone treatment or would need to be used in
conjunction with other interventions has yet to be deter-
mined. Future, long-term studies with larger sample
sizes and participants with various severities of depres-
sion will be needed. Several potential limitations of the
current study should be noted. First, the study was only
single blinded. While the examiner was blinded to group
allocation during all blood analysis, participants were
aware of their group assignment. Although placebo sup-
plements could have been provided to the control group,
it was not possible to adequately blind participants to all
aspects of the diet. The treatment group underwent a
highly restrictive diet while the control group was free to
consume unhealthy foods making distinction between
groups quite obvious. Second, it is not possible to eluci-
date the specific mechanisms related to the reductions
in inflammation, nor is it possible to discern which as-
pects of the dietary intervention may have had the stron-
gest effects. It will be necessary for future studies to
examine aspects such as transcription factor activity
and membrane composition in order to truly eluci-
date the means by which such interventions act to
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reduce inflammation and improve symptoms of neuro-
pathic pain. In terms of generalizability, our sample was
quite representative of the SCI population in Canada, in
terms of age, level, and severity of injury [41]; however,
the results may not necessarily be generalizable to all indi-
viduals with SCI with varying levels of inflammation and
severities of depression (however, it is of interest that all
participants with scores indicating depression improved to
a score indicating a lack of depression in the current
study). Finally, it is worth noting that utilizing an interven-
tion which targets inflammation by such means as diet or
exercise requires a commitment to a major lifestyle modi-
fication and may not provide the same immediacy of ef-
fects as traditional pharmaceuticals. Still, the current
study showed strong compliance to the diet and achieved
significant reductions in CES-D scores after only 1 month.
Further, given the lack of side effects, and additional
health benefits that coincide with healthy eating, such in-
terventions may be a viable mode of treatment for this
population and are worthy of further examination.
Conclusions
The present study demonstrated that it was possible to
improve mood in individuals with SCI by means of redu-
cing inflammation. Such improvements may relate to
positive changes in neuroactive compounds of the kynure-
nine pathway mediated by the significant reduction
achieved in the pro-inflammatory cytokine IL-1β. These
results suggest a potential role for anti-inflammatory in-
terventions in the treatment of depression in spinal cord-
injured individuals. Due to the limited sample size of the
present study, the results should be interpreted with cau-
tion. However, this influence is worthy of further examin-
ation in future larger-scale studies, as it may help to
reduce the reliance on traditional pharmaceuticals by
complementing current treatments or by providing a safe
and sustainable treatment alternative.
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